'%3e%3cpath%20d='M22.1642%2019.0924C21.7317%2018.068%2021.1041%2017.1375%2020.3163%2016.3527C19.5309%2015.5656%2018.6006%2014.9381%2017.5766%2014.5048C17.5674%2014.5002%2017.5582%2014.4979%2017.5491%2014.4933C18.9774%2013.4616%2019.9059%2011.7811%2019.9059%209.88504C19.9059%206.74408%2017.3611%204.19922%2014.2201%204.19922C11.0792%204.19922%208.53429%206.74408%208.53429%209.88504C8.53429%2011.7811%209.46282%2013.4616%2010.8912%2014.4956C10.882%2014.5002%2010.8728%2014.5025%2010.8636%2014.5071C9.83652%2014.9404%208.91487%2015.5617%208.1239%2016.355C7.33685%2017.1404%206.70933%2018.0707%206.276%2019.0947C5.85031%2020.0972%205.62072%2021.172%205.59967%2022.2609C5.59905%2022.2853%205.60335%2022.3097%205.61229%2022.3325C5.62123%2022.3553%205.63465%2022.376%205.65174%2022.3935C5.66883%2022.4111%205.68926%2022.425%205.71182%2022.4345C5.73437%2022.444%205.7586%2022.4489%205.78308%2022.4489H7.15868C7.25956%2022.4489%207.3398%2022.3686%207.3421%2022.2701C7.38795%2020.5001%208.09868%2018.8425%209.35506%2017.5861C10.655%2016.2862%2012.3814%2015.5709%2014.2201%2015.5709C16.0588%2015.5709%2017.7852%2016.2862%2019.0852%2017.5861C20.3415%2018.8425%2021.0523%2020.5001%2021.0981%2022.2701C21.1004%2022.3709%2021.1807%2022.4489%2021.2815%2022.4489H22.6571C22.6816%2022.4489%2022.7058%2022.444%2022.7284%2022.4345C22.751%2022.425%2022.7714%2022.4111%2022.7885%2022.3935C22.8056%2022.376%2022.819%2022.3553%2022.8279%2022.3325C22.8369%2022.3097%2022.8412%2022.2853%2022.8406%2022.2609C22.8176%2021.165%2022.5907%2020.0989%2022.1642%2019.0924ZM14.2201%2013.8284C13.1678%2013.8284%2012.1773%2013.418%2011.4322%2012.6729C10.6871%2011.9278%2010.2767%2010.9374%2010.2767%209.88504C10.2767%208.83271%2010.6871%207.84227%2011.4322%207.09715C12.1773%206.35204%2013.1678%205.94165%2014.2201%205.94165C15.2724%205.94165%2016.2629%206.35204%2017.008%207.09715C17.7531%207.84227%2018.1635%208.83271%2018.1635%209.88504C18.1635%2010.9374%2017.7531%2011.9278%2017.008%2012.6729C16.2629%2013.418%2015.2724%2013.8284%2014.2201%2013.8284Z'%20fill='%238590A2'/%3e%3c/g%3e%3c/svg%3e)
Co-authors
Following
Followers
Research Focus & Metrics
Explore full metrics on Scilit
Academic Career Length
22Years (2005-Present)
(Calculated once Scilit publication data is synced: current year − year of first publication + 1)
Representative Publications
View All Publications10 September 2017 in European Respiratory Journal
Journal Article
Antoni TorresMNMichael S. Niederman
Michael S. Niederman
JCJean Chastre
Jean Chastre
SESantiago Ewig
Santiago Ewig
PFPatricia Fernandez-Vandellos
Patricia Fernandez-Vandellos
RWRichard Wunderink
Richard Wunderink
+10
The most recent European guidelines and task force reports on hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) were published almost 10 years ago. Since then, further randomised clinical trials of HAP and VAP have been conducted and new information has become available. Studies of epidemiology, diagnosis, empiric treatment, response to treatment, new antibiotics or new forms of antibiotic administration and disease prevention have changed old paradigms. In addition, important differences between approaches in Europe and the USA have become apparent.The European Respiratory Society launched a project to develop new international guidelines for HAP and VAP. Other European societies, including the European Society of Intensive Care Medicine and the European Society of Clinical Microbiology and Infectious Diseases, were invited to participate and appointed their representatives. The Latin American Thoracic Association was also invited.A total of 15 experts and two methodologists made up the panel. Three experts from the USA were also invited (Michael S. Niederman, Marin Kollef and Richard Wunderink).Applying the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) methodology, the panel selected seven PICO (population–intervention–comparison–outcome) questions that generated a series of recommendations for HAP/VAP diagnosis, treatment and prevention.
8 April 2021 in Nature Reviews Disease Primers
Journal Article
Antoni Torres
Catia CillonizMNMichael S. Niederman
Michael S. NiedermanRMRosario Menéndez
Rosario Menéndez
JCJames D. Chalmers
James D. Chalmers
TPTom van der Poll
Tom van der Poll
+1
15 October 2013 in Thorax
Journal Article
Antoni TorresWPWilly E Peetermans
Willy E Peetermans
GVGiovanni Viegi
Giovanni Viegi
Francesco BlasiBackground Community-acquired pneumonia (CAP) causes considerable morbidity and mortality in adults, particularly in the elderly. Methods Structured searches of PubMed were conducted to identify up-to-date information on the incidence of CAP in adults in Europe, as well as data on lifestyle and medical risk factors for CAP. Results The overall annual incidence of CAP in adults ranged between 1.07 to 1.2 per 1000 person-years and 1.54 to 1.7 per 1000 population and increased with age (14 per 1000 person-years in adults aged ≥65 years). Incidence was also higher in men than in women and in patients with chronic respiratory disease or HIV infection. Lifestyle factors associated with an increased risk of CAP included smoking, alcohol abuse, being underweight, having regular contact with children and poor dental hygiene. The presence of comorbid conditions, including chronic respiratory and cardiovascular diseases, cerebrovascular disease, Parkinson's disease, epilepsy, dementia, dysphagia, HIV or chronic renal or liver disease all increased the risk of CAP by twofold to fourfold. Conclusion A range of lifestyle factors and underlying medical conditions are associated with an increased risk of CAP in European adults. Understanding of the types of individual at greatest risk of CAP can help to ensure that interventions to reduce the risk of infection and burden of disease are targeted appropriately.
17 February 2015 in JAMA
Journal Article
Antoni TorresOVOriol Sibila Vidal
Oriol Sibila VidalMFMiquel Ferrer
Miquel Ferrer
Eva PolverinoRMRosario Menéndez
Rosario MenéndezCACarles Agustí
Carles Agustí
+6
Community-acquired pneumonia is the leading infectious cause of death in developed countries. Despite advances in antibiotic treatment, mortality among hospitalized patients with community-acquired pneumonia is still high, especially in those with severe pneumonia1,2 and in those who experience treatment failure3,4 (observed in 10%-20% of patients). In an earlier study conducted by the Neumofail Group,3 patients with treatment failure had higher mortality compared with those who did not experience treatment failure (25% vs 2%, respectively), and it was possible to use treatment failure as a surrogate parameter for mortality. In patients with community-acquired pneumonia, an excessive host inflammatory response is associated with treatment failure during intensive care unit (ICU) admission5 and mortality.6
1 September 2015 in The Lancet
Journal Article
1 March 2018 in The Lancet Infectious Diseases
Journal Article
Antoni TorresNZNanshan Zhong
Nanshan Zhong
JPJan Pachl
Jan Pachl
JTJean-François Timsit
Jean-François Timsit
MKMarin Kollef
Marin Kollef
JCJoseph W Chow
Joseph W Chow +5
About Me
Prof. Antoni Torres is a Medical Doctor of the Department
of Pulmonology and Respiratory Allergy, Clinical Institute of Thorax, Hospital
Clínic of Barcelona, University of Barcelona. He is also a Professor of
Medicine in the Faculty of Medicine, University of Barcelona, Spain. He is the
Chief of the Respiratory Intensive Care Unit of Hospital Clínic of Barcelona
and Coordinator of all ICUs at the Clinic Thorax Institute of Hospital Clínic
of Barcelona. His previous appointments include Head of the Department of
Pneumology and Respiratory Allergy of the Hospital Clínic of Barcelona
(2004–2010). Prof. Torres attained his degree in medicine from the University
of Barcelona and his residency in Pneumology at the Hospital Clínic of
Barcelona. His other specialties include internal medicine, laboral medicine,
and intensive care. Prof. Torres also has a Masters in Hospital Management from
the University of Barcelona. He is an active member of many medical societies,
and was previously Vice President of the Spanish Society of Pneumology and
Thoracic Surgery and Chairman of the Respiratory Intensive Care Assembly of the
European Respiratory Society. He was also nominated for the vice-presidency of
the European Respiratory Society in 2011 and 2012. Prof. Torres has received
many awards for scientific achievement, the most recent being a Fellowship of
the European Respiratory Society in 2014 for his contribution to research in
the respiratory field.